Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033

Report Highlights

Global Next Generation Sequencing (NGS) Market to Reach $28.47 Billion by 2033

Market Segmentation:

Segmentation 1: by Offering

• Consumables
  • Library Preparation Kits
  • Sequencing Kits
• Equipment
• Services

The global NGS market (by offering) is expected to be dominated by the consumables segment.

Segmentation 2: by Company

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific BioSciences of California, Inc.
• Oxford Nanopore Technologies plc.
• Other Companies

The global NGS market (by company) is expected to be dominated by Illumina, Inc.

Segmentation 3: by Throughput

• High- and Ultra-High-Throughput
• Medium-Throughput
• Low-Throughput

The global NGS market (by throughput) is expected to be dominated by the high- and ultra-high throughput segment.

Segmentation 4: by Technology Type

• Sequencing by Synthesis
• In Torrent Semiconductor Sequencing
• Single Molecule Real-Time Sequencing
• Nanopore Sequencing Technology
• Other Technologies

The global NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.

Segmentation 5: by Sequencing

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing

The global NGS market (by sequencing) is expected to be dominated by the targeted sequencing segment.

Segmentation 6: by Application

• Clinical Diagnostics
  • Oncology
  • Non-Oncology
• Research
  • Oncology
  • Non-Oncology

The global NGS market (by application) is expected to be dominated by the research segment. Within further sub-segmentation, the market is expected to be dominated by the oncology segment.

Segmentation 7: by End User

• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Other End Users

The global NGS market (by end user) is expected to be dominated by the academic and research insitutes segment.

Segmentation 8: by Country

• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific - Japan, India, China, South Korea, Australia, Singapore, New Zealand, and Rest-of-Asia-Pacific
• Middle East - U.A.E., K.S.A., Israel, Rest-of-Middle East
• Rest-of-the-World - Latin America, Rest-of-Rest-of-the-World

Note: Each country is further segmented by offering, equipment (units), and company.

Recent Developments in the Global NGS Market

• In April 2023, NGeneBio signed a business agreement with Agilent Technologies, Inc.’s Korea-based subsidiary, to expand the NGS precision diagnosis in South Korea and abroad.
• In March 2023, Sophia Genetics partnered with Agilent Technologies Inc. to integrate its Sophia DDM Platform with Agilent Technologies Inc.’s research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay kit.
• In March 2023, Thermo Fisher Scientific Inc. collaborated with Pfizer to expand access to NGS-based lung and breast cancer testing in more than 30 countries.
• In January 2023, Qiagen N.V. completed the acquisition of Verogen, Inc. in order to deploy next-generation biometrics for forensic and molecular testing.
• In October 2022, Pacific Biosciences of California, Inc. introduced two new sequencing systems, namely, Revio and Onso.
• In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.

Demand - Drivers and Limitations

The following are the drivers for the global NGS market:

• Decreasing Cost of Genome Sequencing
• Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings
• Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare
• Advantages of NGS Technology Over Other Technologies

The market is expected to face some limitations as well due to the following challenges:

• Concerns Surrounding Privacy of Patient Genomic Data
• Lack of Complete Reimbursement Coverage for NGS Testing

How can this report add value to an organization?

Type: The global NGS market has been extensively segmented on the basis of various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., nearly 85% of the total developments in the global NGS market.

Competitive Strategy: The global NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the global NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.

Impact of COVID-19

NGS has played a crucial role in the genomic surveillance of SARS-CoV-2, the virus responsible for COVID-19. Sequencing the viral genome has helped in tracking the spread of different variants and understanding their genetic characteristics, which has been essential for public health efforts, vaccine development, and treatment strategies. NGS has been employed in studies investigating the genetic susceptibility to COVID-19 and its severity. By sequencing the genomes of affected individuals, researchers have sought to identify genetic variations associated with the risk of infection, disease progression, and response to treatment.

However, while NGS testing shot up in the research laboratories studying the transmission of the SARS-CoV-2 virus, NGS testing in the clinical setting witnessed a significant drop. The global supply chain for NGS instruments, consumables, and reagents experienced severe disruptions due to the pandemic. Manufacturing and shipping delays impacted the availability of NGS products and tests, especially in developing regions such as the Middle East, Africa, or Rest-of-the-World.